Higher Blood Flow with New Hemodialysis Catheter

A new hemodialysis catheter is designed to improve long-term vascular access and facilitate therapy for patients suffering from end-stage renal failure (EESRD). Currently, dialysis therapy or a kidney transplant is the only treatment available for kidney failure.

The catheter not only provides higher blood flows at lower pressures compared to competing catheters but also offers kink resistance and minimal recirculation. Called the Pourchez Xpresso catheter, the catheter has been cleared by the US Food and Drug Administration (FDA). The device was developed by Spire Biomedical, Inc. (Bedford, MA, USA), a subsidiary of Spire Corp.

"There is a dire need for advances in hemodialysis catheter design,” said Dr. Thomas M. Vesely, associate professor of radiology and surgery at the School of Medicine at Washington University (St. Louis, MO, USA).”I am very excited by the unique combination of benefits offered by the Pourchez Xpressso and look forward to using it in my practice.”




Related Links:
Spire